Celgene Corporation

129.71 -0.58(-0.45%) Date:

Celgene Corporation

Celgene Corporation (CELG): Ozanimod Worth $19/sh, Range Is $12-25 on RRMS & IBD Results

Today Leerink is publishing its second of two notes on Celgene Corporation’s (NASDAQ:CELG) ozanimod that focuses on the product’s value; in its current forecast the firm estimates that ozanimod is worth $19/ share (13% of its PT) in the base case scenario in its model

Here's Why Celgene Corporation (CELG) Collaborate With BeiGene

Celgene reported that BeiGene will retain exclusive rights for the development and commercialization of BGB-A317 for hematological malignancies globally and for solid tumors in Asia, except Japan

Celgene Corporation (CELG): Ozanimod Safety Advantage vs. Gilenya To Drive Market Adoption

Canaccord Genuity believes that much lower cardiovascular Adverse Events and liver toxicity for Ozanimod in Multiple Sclerosis will indeed drive much higher usage for Celgene Corporation vs. Gilenya, and could surprise the Street

Celgene Corporation (CELG) MAGNIFY Data Continues To Look Good

BMO Capital Markets' big takeaway is the data continues to improve with every update and the trial is still enrolling (ASCO data as of January 9, 2017)

Celgene Corporation (CELG) Ozanimod MS Estimates Increase By 2-4x On Significant Disability Benefit

A disability benefit could double BMO Capital Markets' $1B peak MS sales estimate, with upside to 4x dependent on a differentiated safety profile